{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T12:17:43Z","timestamp":1780402663794,"version":"3.54.1"},"reference-count":17,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:00:00Z","timestamp":1731456000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013988","name":"Dermira","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013988","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.clinthera.2024.10.016","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T12:41:11Z","timestamp":1733316071000},"page":"55-61","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Evaluation of Pharmacokinetics of Lebrikizumab in Healthy Individuals After Subcutaneous Administration Using a Prefilled Syringe or Autoinjector in a Phase 1 Randomized Study"],"prefix":"10.1016","volume":"47","author":[{"given":"Amita","family":"Datta-Mannan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Moser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberley","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Witcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April W.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Blauvelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Lio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2024.10.016_bib0001","first-page":"39","article-title":"Biologic treatments of psoriasis: an update for the clinician","volume":"15","author":"Brownstone","year":"2021","journal-title":"Biologics"},{"key":"10.1016\/j.clinthera.2024.10.016_bib0002","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1111\/jdv.15913","article-title":"A systematic review of factors influencing treatment adherence in chronic inflammatory skin disease\u2014strategies for optimizing treatment outcome","volume":"33","author":"Eicher","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clinthera.2024.10.016_bib0003","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.jsps.2021.09.004","article-title":"Autoinjector\u2014a smart device for emergency cum personal therapy","volume":"29","author":"Roy","year":"2021","journal-title":"Saudi Pharm J"},{"key":"10.1016\/j.clinthera.2024.10.016_bib0004","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jaad.2013.10.010","article-title":"Guidelines of care for the management of atopic dermatitis: Section 1. Diagnosis and assessment of atopic dermatitis","volume":"70","author":"Eichenfield","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clinthera.2024.10.016_bib0005","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1177\/1203475420982553","article-title":"Inhibition of IL-13: a new pathway for atopic dermatitis","volume":"25","author":"Ratnarajah","year":"2021","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.clinthera.2024.10.016_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7573\/dic.2021-1-7","article-title":"Selective IL-13 inhibitors for the treatment of atopic dermatitis","volume":"10","author":"Gon\u00e7alves","year":"2021","journal-title":"Drugs Context"},{"key":"10.1016\/j.clinthera.2024.10.016_bib0007","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2018.01.017","article-title":"Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: a randomized, placebo-controlled phase II trial (TREBLE)","volume":"78","author":"Simpson","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clinthera.2024.10.016_bib0008","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s13555-023-00947-7","article-title":"Binding, neutralization and internalization of the interleukin-13 antibody, lebrikizumab","volume":"13","author":"Okragly","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.clinthera.2024.10.016_bib0009","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jamadermatol.2020.0079","article-title":"Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial","volume":"156","author":"Guttman-Yassky","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clinthera.2024.10.016_bib0010","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/bjd\/ljad022","article-title":"Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials","volume":"188","author":"Blauvelt","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clinthera.2024.10.016_bib0011","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2206714","article-title":"Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis","volume":"388","author":"Silverberg","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2024.10.016_bib0012","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.pupt.2017.08.010","article-title":"Model-based clinical pharmacology profiling and exposure-response relationships of the efficacy and biomarker of lebrikizumab in patients with moderate-to-severe asthma","volume":"46","author":"Zhu","year":"2017","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2024.10.016_bib0013","series-title":"Presented at American Conference on Pharmacometrics (ACoP), November 5\u20138","article-title":"Population pharmacokinetic modeling of lebrikizumab in adults and adolescents [poster M-034]","author":"Moser","year":"2023"},{"key":"10.1016\/j.clinthera.2024.10.016_bib0014","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jconrel.2021.06.038","article-title":"Impact of injection sites on clinical pharmacokinetics of subcutaneously administered peptides and proteins","volume":"336","author":"Zou","year":"2021","journal-title":"J Control Release"},{"key":"10.1016\/j.clinthera.2024.10.016_bib0015","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S2213-2600(16)30265-X","article-title":"Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials","volume":"4","author":"Hanania","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.clinthera.2024.10.016_bib0016","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1001\/jamadermatol.2022.5534","article-title":"Efficacy and safety of lebrikizumab in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis: a randomized clinical trial (ADhere)","volume":"159","author":"Simpson","year":"2023","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clinthera.2024.10.016_bib0017","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1007\/s13555-023-00942-y","article-title":"Safety and efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: a 52-week, open-label, phase 3 study","volume":"13","author":"Paller","year":"2023","journal-title":"Dermatol Ther (Heidelb)"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824003230?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824003230?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T19:57:17Z","timestamp":1736366237000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291824003230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0149291824003230"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.10.016","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of Pharmacokinetics of Lebrikizumab in Healthy Individuals After Subcutaneous Administration Using a Prefilled Syringe or Autoinjector in a Phase 1 Randomized Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.10.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Eli Lilly and Company. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}